459 related articles for article (PubMed ID: 24618337)
1. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
Li P; Yang R; Gao WQ
Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
4. Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target.
Castellón EA; Indo S; Contreras HR
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499245
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.
Kong D; Sethi S; Li Y; Chen W; Sakr WA; Heath E; Sarkar FH
Prostate; 2015 Feb; 75(2):161-74. PubMed ID: 25307492
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
[TBL] [Abstract][Full Text] [Related]
7. A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer.
Shang Z; Cai Q; Zhang M; Zhu S; Ma Y; Sun L; Jiang N; Tian J; Niu X; Chen J; Sun Y; Niu Y
Oncotarget; 2015 Jan; 6(2):1202-16. PubMed ID: 25483103
[TBL] [Abstract][Full Text] [Related]
8. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma.
Laudato S; Aparicio A; Giancotti FG
Trends Cancer; 2019 Jul; 5(7):440-455. PubMed ID: 31311658
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
10. The Transcription Factors Zeb1 and Snail Induce Cell Malignancy and Cancer Stem Cell Phenotype in Prostate Cells, Increasing Androgen Synthesis Capacity and Therapy Resistance.
López-Moncada F; Castellón EA; Contreras HR
Adv Exp Med Biol; 2022; 1393():51-64. PubMed ID: 36587301
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome profiling reveals that VNPP433-3β, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers.
Thomas E; Thankan RS; Purushottamachar P; Huang W; Kane MA; Zhang Y; Ambulos N; Weber DJ; Njar VCO
Mol Carcinog; 2022 Jul; 61(7):643-654. PubMed ID: 35512605
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition in prostate cancer: an overview.
Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
[TBL] [Abstract][Full Text] [Related]
13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
14. Therapy escape mechanisms in the malignant prostate.
Santer FR; Erb HH; McNeill RV
Semin Cancer Biol; 2015 Dec; 35():133-44. PubMed ID: 26299608
[TBL] [Abstract][Full Text] [Related]
15. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.
Ruan D; He J; Li CF; Lee HJ; Liu J; Lin HK; Chan CH
Oncogene; 2017 Jul; 36(30):4299-4310. PubMed ID: 28346424
[TBL] [Abstract][Full Text] [Related]
16. A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics.
Harner-Foreman N; Vadakekolathu J; Laversin SA; Mathieu MG; Reeder S; Pockley AG; Rees RC; Boocock DJ
Sci Rep; 2017 Jan; 7():40633. PubMed ID: 28094783
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells.
Zhifang M; Liang W; Wei Z; Bin H; Rui T; Nan W; Shuhai Z
BMC Biochem; 2015 May; 16():13. PubMed ID: 25943311
[TBL] [Abstract][Full Text] [Related]
18. Lessons from in-vivo models of castration-resistant prostate cancer.
Lin D; Gout PW; Wang Y
Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
[TBL] [Abstract][Full Text] [Related]
19. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links.
Liu X; Fan D
Curr Pharm Des; 2015; 21(10):1279-91. PubMed ID: 25506898
[TBL] [Abstract][Full Text] [Related]
20. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.
Nantajit D; Lin D; Li JJ
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1697-713. PubMed ID: 25270087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
